Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff CF14 4XN, United Kingdom;
Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff CF14 4XN, United Kingdom.
J Immunol. 2019 Feb 1;202(3):943-955. doi: 10.4049/jimmunol.1701757.
Candidate vaccines designed to generate T cell-based immunity are typically vectored by nonpersistent viruses, which largely fail to elicit durable effector memory T cell responses. This limitation can be overcome using recombinant strains of CMV. Proof-of-principle studies have demonstrated the potential benefits of this approach, most notably in the SIV model, but safety concerns require the development of nonreplicating alternatives with comparable immunogenicity. In this study, we show that IL-33 promotes the accumulation and recall kinetics of circulating and tissue-resident memory T cells in mice infected with murine CMV. Using a replication-deficient murine CMV vector, we further show that exogenous IL-33 boosts vaccine-induced memory T cell responses, which protect against subsequent heterologous viral challenge. These data suggest that IL-33 could serve as a useful adjuvant to improve the efficacy of vaccines based on attenuated derivatives of CMV.
候选疫苗旨在产生基于 T 细胞的免疫,通常由非持续性病毒载体,这在很大程度上未能引起持久的效应记忆 T 细胞反应。使用 CMV 的重组株可以克服这一限制。原理验证研究表明了这种方法的潜在益处,在 SIV 模型中最为明显,但安全性问题需要开发具有可比免疫原性的非复制替代品。在这项研究中,我们表明 IL-33 促进了感染鼠 CMV 的小鼠中循环和组织驻留记忆 T 细胞的积累和回忆动力学。使用复制缺陷型鼠 CMV 载体,我们进一步表明外源性 IL-33 增强了疫苗诱导的记忆 T 细胞反应,从而防止随后的异源病毒攻击。这些数据表明,IL-33 可以作为一种有用的佐剂,提高基于 CMV 减毒衍生物的疫苗的疗效。